Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 23	APR 03	CAS coverage of exemplified prophetic substances enhanced

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:02:02 ON 06 APR 2009

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 13:02:11 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2
DICTIONARY FILE UPDATES: 5 APR 2009 HIGHEST RN 1132636-28-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10564139s1.str



```
chain nodes :
13
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  14  15  16  17  18  19  20  21  22
chain bonds :
6-7  10-13  13-14
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  14-15  14-19
15-16  16-17  16-20  17-18  17-22  18-19  20-21  21-22
exact/norm bonds :
6-7  7-8  7-12  8-9  9-10  10-11  10-13  11-12  16-20  17-22  20-21  21-22
exact bonds :
13-14
normalized bonds :
1-2  1-6  2-3  3-4  4-5  5-6  14-15  14-19  15-16  16-17  17-18  18-19


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:CLASS  14:Atom  15:Atom  16:Atom  17:Atom  18:Atom  19:Atom
20:Atom  21:Atom  22:Atom



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1 sss sam
SAMPLE SEARCH INITIATED 13:02:26 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       56 TO ITERATE

100.0% PROCESSED       56 ITERATIONS                              12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
```

```
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          671 TO     1569
PROJECTED ANSWERS:              33 TO      447

L2           12 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 13:02:29 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     1306 TO ITERATE

100.0% PROCESSED     1306 ITERATIONS                              301 ANSWERS
SEARCH TIME: 00.00.01

L3          301 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                              SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                 185.88     186.10

FILE 'CAPLUS' ENTERED AT 13:02:33 ON 06 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 6 Apr 2009  VOL 150 ISS 15
FILE LAST UPDATED: 5 Apr 2009  (20090405/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=>  s l3 and nasal and (aqueous or spray or powder)
          482 L3
        26074 NASAL
            1 NASALS
        26075 NASAL
                (NASAL OR NASALS)
       210171 AQUEOUS
            1 AQUEOUSES
       210172 AQUEOUS
                (AQUEOUS OR AQUEOUSES)
      1148784 AQ
          206 AQS
      1148912 AQ
```

```
              (AQ OR AQS)
       1203178 AQUEOUS
               (AQUEOUS OR AQ)
        155126 SPRAY
         35610 SPRAYS
        175425 SPRAY
               (SPRAY OR SPRAYS)
        627288 POWDER
        219593 POWDERS
        725519 POWDER
               (POWDER OR POWDERS)
        202446 POWD
           255 POWDS
        202573 POWD
               (POWD OR POWDS)
        854343 POWDER
               (POWDER OR POWD)
L4           1 L3 AND NASAL AND (AQUEOUS OR SPRAY OR POWDER)

=> d ibib abs hitstr 1

L4   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2005:56829  CAPLUS
DOCUMENT NUMBER:          142:141273
TITLE:                    Pharmaceutical composition for the nasal
                          administration of piribedil
INVENTOR(S):              Rolland, Herve; Wuthrich, Patrick
PATENT ASSIGNEE(S):       Les Laboratoires Servier, Fr.; Servier Lab
SOURCE:                   Fr. Demande, 9 pp.
                          CODEN: FRXXBL
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     FR 2857594           A1    20050121    FR 2003-8712           20030717
     FR 2857594           B1    20050916
     AU 2004258714        A1    20050203    AU 2004-258714         20040716
     CA 2532631           A1    20050203    CA 2004-2532631        20040716
     WO 2005009442        A1    20050203    WO 2004-FR1867         20040716
          W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
              CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
              GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
              LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
              NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
              TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
          RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
              AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
              EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
              SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
              SN, TD, TG
     EP 1653963           A1    20060510    EP 2004-767691         20040716
     EP 1653963           B1    20061227
          R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
     CN 1819828           A     20060816    CN 2004-80019749       20040716
     BR 2004012681        A     20061003    BR 2004-12681          20040716
     AT 349213            T     20070115    AT 2004-767691         20040716
     JP 2007516947        T     20070628    JP 2006-519966         20040716
     ES 2279435           T3    20070816    ES 2004-767691         20040716
```

NZ 544460	A	20080430	NZ 2004-544460		20040716
IN 2006DN00118	A	20070824	IN 2006-DN118		20060106
US 20060204449	A1	20060914	US 2006-564139		20060110
MX 2006000641	A	20060330	MX 2006-641		20060117
KR 2006031689	A	20060412	KR 2006-701141		20060117
KR 807480	B1	20080225			
NO 2006000743	A	20060216	NO 2006-743		20060216
PRIORITY APPLN. INFO.:			FR 2003-8712	A	20030717
			WO 2004-FR1867	W	20040716

AB The present invention relates to a pharmaceutical composition for the nasal administration of piribedil in solution or powder forms. Thus, a formulation contained piribedil 100, Rameb (randomly methylated cyclodextrin) 750, and NaCl 68 mg, and water qs to 10 mL.

IT 3605-01-4, Piribedil
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition for nasal administration of piribedil)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> s l3 and nasal
          482 L3
        26074 NASAL
            1 NASALS
        26075 NASAL
                (NASAL OR NASALS)
L5          7 L3 AND NASAL

=> d ibib abs hitstr 1-7

L5   ANSWER 1 OF 7  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2009:233290  CAPLUS
DOCUMENT NUMBER:          150:252678
TITLE:                    Combinations containing MPO inhibitors against
                          neuroinflammatory disorders
INVENTOR(S):              Aahlberg, Gabrielle; Eriksson, Haakan
PATENT ASSIGNEE(S):       Astrazeneca AB, Swed.
SOURCE:                   PCT Int. Appl., 41pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ----------------    ----   --------    ---------------------  --------
     WO 2009025617       A1     20090226    WO 2008-SE50949        20080822
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
```

FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20090053176 A1 20090226 US 2008-195505 20080821

PRIORITY APPLN. INFO.: US 2007-957524P P 20070823

AB The present invention related to a combination of (a) a compound which is a MPO inhibitor or a pharmaceutically acceptable salt thereof and (b) a compound or a pharmaceutically acceptable salt thereof, which is used in the treatment and/or prevention of PD or Multiple Sclerosis. The invention further relates to pharmaceutical compns. comprising said combination and to methods of treating Neuroinflammatory and Neurodegenerative Disorder(s), such as PD and Multiple Sclerosis in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of Neuroinflammatory Disorder(s).

IT 3605-01-4, Piribedil

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(combinations containing MPO inhibitors against neuroinflammatory disorders)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1359892 CAPLUS

DOCUMENT NUMBER: 149:519140

TITLE: Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders

INVENTOR(S): Braun, Marina; Schollmayer, Erwin; Sachse, Richard

PATENT ASSIGNEE(S): Schwarz Pharma A.-G., Germany

SOURCE: PCT Int. Appl., 58pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008135527	A2	20081113	WO 2008-EP55413	20080502
WO 2008135527	A3	20090212		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
EP 1987815 A1 20081105 EP 2007-9013 20070504
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR,
AL, BA, HR, MK, RS
PRIORITY APPLN. INFO.: EP 2007-9013 A 20070504
US 2007-915964P P 20070504

AB The present invention relates to use of a dopamine agonist such as rotigotine for the preparation of an oronasopharyngeally deliverable pharmaceutical composition for the prevention/alleviation and/or treatment of restless limb disorder, as well as pharmaceutical articles, dosage units and pharmaceutical kits useful in practicing the invention. Thus, intranasal formulation was prepared containing rotigotine hydrochloride 2.5 g/l, α-cyclodextrin 85 g/l, sodium chloride 8 g/l, potassium chloride 0.2 g/l, disodium hydrogen phosphate dihydrate 1.44 g/l, potassium dihydrogen phosphate 0.2 g/l, glycerol 31.2 g/l, water to add up to final volume, and citric acid for pH adjustment (pH of solution 5.8).

IT 3605-01-4, Piribedil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oronasopharyngeally deliverable pharmaceutical compns. of dopamine agonists for prevention and/or treatment of restless limb disorders)
RN 3605-01-4 CAPLUS
CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2008:1324859 CAPLUS
DOCUMENT NUMBER: 149:500102
TITLE: Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
PATENT ASSIGNEE(S): Schwarz Pharma A.-G., Germany
SOURCE: Eur. Pat. Appl., 33pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1987815	A1	20081105	EP 2007-9013	20070504

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS

US 20080274061 A1 20081106 US 2008-114348 20080502
WO 2008135527 A2 20081113 WO 2008-EP55413 20080502
WO 2008135527 A3 20090212

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: EP 2007-9013 A 20070504
US 2007-915964P P 20070504

AB The present invention relates to use of a dopamine agonist such as rotigotine for the preparation of an oronasopharyngeally deliverable pharmaceutical composition for the prevention/alleviation and/or treatment of restless limb disorder, as well as pharmaceutical articles, dosage units and pharmaceutical kits useful in practicing the invention. Thus, intranasal formulation was prepared containing rotigotine hydrochloride 2.5 g/l, α-cyclodextrin 85 g/l, sodium chloride 8 g/l, potassium chloride 0.2 g/l, disodium hydrogen phosphate dihydrate 1.44 g/l, potassium dihydrogen phosphate 0.2 g/l, glycerol 31.2 g/l, water to add up to final volume, and citric acid for pH adjustment (pH of solution 5.8).

IT 3605-01-4, Piribedil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(oronasopharyngeally deliverable pharmaceutical compns. of dopamine agonists for prevention and/or treatment of restless limb disorders)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:284134 CAPLUS
DOCUMENT NUMBER: 142:349472
TITLE: As-needed administration of an androgenic agent to enhance female desire and responsiveness
INVENTOR(S): Wilson, Leland F.; Tam, Peter Y.
PATENT ASSIGNEE(S): Vivus Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 19 pp., Cont.-in-part of U.S. Ser. No. 919,472.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050070516	A1	20050331	US 2004-990667	20041116
US 5877216	A	19990302	US 1997-959064	19971028
US 6306841	B1	20011023	US 2000-539484	20000330
US 20020013304	A1	20020131	US 2001-919472	20010727
PRIORITY APPLN. INFO.:			US 1997-959057	B2 19971028
			US 1997-959064	A2 19971028
			US 1998-181316	B1 19981027
			US 2000-539484	A2 20000330
			US 2001-919472	A2 20010727

AB A method is provided for enhancing a female individual's sexual desire and responsiveness. The method involves administration of a pharmaceutical formulation containing an effective amount of an androgenic agent, wherein administration is on an as-needed basis rather than involving chronic pharmacotherapy. Local delivery may be accomplished via administration to the vagina, vulvar area or urethra of the individual, although oral administration is preferred for those androgenic agents that are orally active. Formulations and kits for carrying out the method are provided as well.

IT 3605-01-4, Piribedil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as addnl. active agents; as-needed administration of an androgenic agent to enhance female desire and responsiveness)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:56829 CAPLUS
DOCUMENT NUMBER: 142:141273
TITLE: Pharmaceutical composition for the nasal administration of piribedil
INVENTOR(S): Rolland, Herve; Wuthrich, Patrick
PATENT ASSIGNEE(S): Les Laboratoires Servier, Fr.; Servier Lab
SOURCE: Fr. Demande, 9 pp.
CODEN: FRXXBL
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2857594	A1	20050121	FR 2003-8712	20030717
FR 2857594	B1	20050916		
AU 2004258714	A1	20050203	AU 2004-258714	20040716
CA 2532631	A1	20050203	CA 2004-2532631	20040716
WO 2005009442	A1	20050203	WO 2004-FR1867	20040716

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1653963	A1	20060510	EP 2004-767691		20040716
EP 1653963	B1	20061227			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

CN 1819828	A	20060816	CN 2004-80019749		20040716
BR 2004012681	A	20061003	BR 2004-12681		20040716
AT 349213	T	20070115	AT 2004-767691		20040716
JP 2007516947	T	20070628	JP 2006-519966		20040716
ES 2279435	T3	20070816	ES 2004-767691		20040716
NZ 544460	A	20080430	NZ 2004-544460		20040716
IN 2006DN00118	A	20070824	IN 2006-DN118		20060106
US 20060204449	A1	20060914	US 2006-564139		20060110
MX 2006000641	A	20060330	MX 2006-641		20060117
KR 2006031689	A	20060412	KR 2006-701141		20060117
KR 807480	B1	20080225			
NO 2006000743	A	20060216	NO 2006-743		20060216
PRIORITY APPLN. INFO.:			FR 2003-8712	A	20030717
			WO 2004-FR1867	W	20040716

AB The present invention relates to a pharmaceutical composition for the nasal administration of piribedil in solution or powder forms. Thus, a formulation contained piribedil 100, Rameb (randomly methylated cyclodextrin) 750, and NaCl 68 mg, and water qs to 10 mL.

IT 3605-01-4, Piribedil
RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical composition for nasal administration of piribedil)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER:	1997:500259 CAPLUS
DOCUMENT NUMBER:	127:113363
ORIGINAL REFERENCE NO.:	127:21773a,21776a
TITLE:	Controlled-release bioadhesive pharmaceutical compositions containing vinyl acetate-vinylpyrrolidone copolymer
INVENTOR(S):	Rault, Isabelle; Pichon, Gerald
PATENT ASSIGNEE(S):	Adir Et Compagnie, Fr.
SOURCE:	Eur. Pat. Appl., 7 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 781550	A1	19970702	EP 1996-402788	19961218
EP 781550	B1	19961218		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
FR 2742989	A1	19970704	FR 1995-15701	19951229
FR 2742989	B1	19980123		
AT 222098	T	20020815	AT 1996-402788	19961218
PT 781550	T	20021129	PT 1996-402788	19961218
ES 2180722	T3	20030216	ES 1996-402788	19961218
CA 2193454	A1	19970630	CA 1996-2193454	19961219
CA 2193454	C	20010724		
NO 9605475	A	19970630	NO 1996-5475	19961219
ZA 9610864	A	19970627	ZA 1996-10864	19961223
AU 9675496	A	19970703	AU 1996-75496	19961223
AU 725283	B2	20001012		
JP 09194395	A	19970729	JP 1996-343671	19961224
CN 1159950	A	19970924	CN 1996-123198	19961227
US 5900247	A	19990504	US 1996-777306	19961227

PRIORITY APPLN. INFO.: FR 1995-15701 A 19951229

AB Bioadhesive pharmaceutical composition for the controlled release of active agents in buccal cavity or through nasal, vaginal, and rectal mucosa are claimed. The bioadhesive compns. contain vinyl acetate-vinylpyrrolidone copolymer (I) and polysaccharides. Dihydroergotamine monomethanesulfonate 0.15, I 5, and ethanol:0.1N HCl (50:50) 10 mL were mixed to obtain a homogeneous solution followed by addition of 0.5 g propylene glycol. The mixture thus obtained was spread on an ethylene-vinyl acetate film and dried at room temperature for 2h. Disks of 1 cm diameter having thickness of 0.2 mm were cut from above film for use.

IT 52293-23-9, Piribedil monomethane sulfonate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(controlled-release bioadhesive pharmaceutical compns. containing vinyl acetate-vinylpyrrolidone copolymer)

RN 52293-23-9 CAPLUS
CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 3605-01-4
CMF C16 H18 N4 O2



CM 2

CRN 75-75-2
CMF C H4 O3 S

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 1995:881856 CAPLUS
DOCUMENT NUMBER: 123:329760
ORIGINAL REFERENCE NO.: 123:58869a,58872a
TITLE: Different effects of dopamine and piribedil (a dopamine D2 agonist) on frog monocular optokinetic nystagmus asymmetry
AUTHOR(S): Jardon, Blandine; Bonaventure, Nicole
CORPORATE SOURCE: Laboratoire de Neurophysiologie et Biologie des Comportements, CNRS, Strasbourg, 67084, Fr.
SOURCE: Vision Research (1995), 35(19), 2665-73
CODEN: VISRAM; ISSN: 0042-6989
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Frog monocular optokinetic nystagmus (OKN) displays a directional asymmetry, reacting only to stimulations in the temporal-nasal (T-N) direction. The nasal-temporal (N-T) component is almost absent. The systemic or intrapretectal injection of Piribedil, a D2 dopamine agonist, provokes the appearance of a N-T component suppressing the monocular OKN asymmetry. Conversely, dopamine or haloperidol (a dopamine antagonist, acting mainly on D2 receptors) have no effect upon the monocular OKN unidirectionality. The monocular OKN N-T component still appears after administration of Piribedil even if this injection is preceded by administration of haloperidol which blocks the dopaminergic D2 receptors. Moreover administration of atropine (a cholinergic muscarinic antagonist) following that of Piribedil suppresses the N-T component; when injected before Piribedil, atropine prevents the appearance of the N-T component. These results suggest that in the expts., Piribedil binds with muscarinic receptors.

IT 3605-01-4, Piribedil
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(different effects of dopamine and piribedil (a dopamine D2 agonist) on frog monocular optokinetic nystagmus asymmetry)

RN 3605-01-4 CAPLUS
CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



=> s l3 and mucousal
482 L3
5 MUCOUSAL

```
L6            0 L3 AND MUCOUSAL

=> s l3 and mucous
           482 L3
         16322 MUCOUS
             1 MUCOUSES
         16322 MUCOUS
                 (MUCOUS OR MUCOUSES)
L7            0 L3 AND MUCOUS

=> s l3 adn mucosal
MISSING OPERATOR L3 ADN
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s l3 and mucosal
           482 L3
         45501 MUCOSAL
             5 MUCOSALS
         45503 MUCOSAL
                 (MUCOSAL OR MUCOSALS)
L8            2 L3 AND MUCOSAL

=> d ibib abs hitstr 1-2

L8   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         2009:233290  CAPLUS
DOCUMENT NUMBER:          150:252678
TITLE:                    Combinations containing MPO inhibitors against
                          neuroinflammatory disorders
INVENTOR(S):              Aahlberg, Gabrielle; Eriksson, Haakan
PATENT ASSIGNEE(S):       Astrazeneca AB, Swed.
SOURCE:                   PCT Int. Appl., 41pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    -------------------     --------
     WO 2009025617        A1    20090226    WO 2008-SE50949         20080822
          W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
              CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
              FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
              KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
              ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
              PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
              TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
          RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
              IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
              TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
              TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
              AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
     US 20090053176        A1    20090226    US 2008-195505          20080821
PRIORITY APPLN. INFO.:                      US 2007-957524P     P   20070823
AB   The present invention related to a combination of (a) a compound which is a
     MPO inhibitor or a pharmaceutically acceptable salt thereof and (b) a
     compound or a pharmaceutically acceptable salt thereof, which is used in the
     treatment and/or prevention of PD or Multiple Sclerosis.  The invention
     further relates to pharmaceutical compns. comprising said combination and
     to methods of treating Neuroinflammatory and Neurodegenerative
```

Disorder(s), such as PD and Multiple Sclerosis in mammals by administrating said combination. The invention further relates to a kit comprising the combination and use of said kit in treatment of Neuroinflammatory Disorder(s).

IT 3605-01-4, Piribedil
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combinations containing MPO inhibitors against neuroinflammatory disorders)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1088890 CAPLUS
DOCUMENT NUMBER: 147:392440
TITLE: Transdermal delivery of systemically active central nervous system drugs
INVENTOR(S): Carrara, Dario Norberto R.; Grenier, Arnaud; Alberti, Igno; Henry, Laetitia; Decaudin, Celine
PATENT ASSIGNEE(S): Switz.
SOURCE: U.S. Pat. Appl. Publ., 24pp., Cont.-in-part of U.S. Ser. No. 634,005.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 7
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20070225379	A1	20070927	US 2007-755923	20070531
WO 2002011768	A1	20020214	WO 2001-EP9007	20010803
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030199426	A1	20031023	US 2003-343570	20030519
US 7214381	B2	20070508		
AU 2004283431	A1	20050506	AU 2004-283431	20041006
CA 2538856	A1	20050506	CA 2004-2538856	20041006
WO 2005039531	A1	20050506	WO 2004-EP11175	20041006
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,				

NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1670433	A1	20060621	EP 2004-790156		20041006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK					
BR 2004014551	A	20061031	BR 2004-14551		20041006
JP 2007508261	T	20070405	JP 2006-530107		20041006
NZ 546106	A	20081031	NZ 2004-546106		20041006
US 20060153905	A1	20060713	US 2006-371042		20060307
US 7335379	B2	20080226			
MX 2006003316	A	20060608	MX 2006-3316		20060324
US 20070098775	A1	20070503	US 2006-634005		20061204
US 7404965	B2	20080729			
US 20090069364	A1	20090312	US 2008-268301		20081110
PRIORITY APPLN. INFO.:			WO 2001-EP9007	W	20010803
			US 2003-343570	A1	20030519
			US 2003-510613P	P	20031010
			WO 2004-EP11175	A1	20041006
			US 2006-371042	A2	20060307
			US 2006-634005	A2	20061204
			WO 2000-EP7533	A	20000803
			US 2007-755923	A2	20070531

AB The invention relates to a transdermal or transmucosal non-occlusive, semi-solid pharmaceutical formulation that includes at least one systemically active agent that acts on the central nervous system (CNS) of a mammal; and a permeation enhancing solvent system present in an amount sufficient to solubilize the at least one active ingredient. The permeation enhancing solvent system includes a pharmaceutically acceptable monoalkyl ether of diethylene glycol; a pharmaceutically acceptable glycol; preferably also a fatty alc. and or a fatty acid; and a mixture of a C2 to C4 alc. and water so that the permeation enhancing solvent system (a) inhibits crystallization of the at least one active ingredient on a skin or mucosal surface of a mammal, (b) reduces or prevents transfer of the formulation to clothing or to another being, (c) modulates biodistribution of the at least one active agent within different layers of skin, (d) facilitates absorption of the at least one active agent by a skin or a mucosal surface of a mammal, or (e) provides a combination of one or more of (a) through (d). A transdermal pharmaceutical contained pramipexole dihydrochloride 2.00, diethylene glycol monoethyl ether 5.00, propylene glycol 15.0, hydroxypropylcellulose 1.50, absolute ethanol 4.0, sodium hydroxide q.s. pH = 8.2, and water q.s. 100.00%.

IT 3605-01-4, Piribedil
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(transdermal delivery of systemically active central nervous system drugs)

RN 3605-01-4 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]- (CA INDEX NAME)



```
=> s l3 and mucosa
          482 L3
        67643 MUCOSA
          311 MUCOSAS
         1496 MUCOSAE
        68485 MUCOSA
                (MUCOSA OR MUCOSAS OR MUCOSAE)
L9            1 L3 AND MUCOSA

=> d ibib abs hitstr 1

L9   ANSWER 1 OF 1  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:         1997:500259  CAPLUS
DOCUMENT NUMBER:          127:113363
ORIGINAL REFERENCE NO.:   127:21773a,21776a
TITLE:                    Controlled-release bioadhesive pharmaceutical
                          compositions containing vinyl acetate-vinylpyrrolidone
                          copolymer
INVENTOR(S):              Rault, Isabelle; Pichon, Gerald
PATENT ASSIGNEE(S):       Adir Et Compagnie, Fr.
SOURCE:                   Eur. Pat. Appl., 7 pp.
                          CODEN: EPXXDW
DOCUMENT TYPE:            Patent
LANGUAGE:                 French
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.         DATE
     --------------      ----   --------    --------------------    --------
     EP 781550           A1     19970702    EP 1996-402788          19961218
     EP 781550           B1     19961218
         R:  AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
     FR 2742989          A1     19970704    FR 1995-15701           19951229
     FR 2742989          B1     19980123
     AT 222098           T      20020815    AT 1996-402788          19961218
     PT 781550           T      20021129    PT 1996-402788          19961218
     ES 2180722          T3     20030216    ES 1996-402788          19961218
     CA 2193454          A1     19970630    CA 1996-2193454         19961219
     CA 2193454          C      20010724
     NO 9605475          A      19970630    NO 1996-5475            19961219
     ZA 9610864          A      19970627    ZA 1996-10864           19961223
     AU 9675496          A      19970703    AU 1996-75496           19961223
     AU 725283           B2     20001012
     JP 09194395         A      19970729    JP 1996-343671          19961224
     CN 1159950          A      19970924    CN 1996-123198          19961227
     US 5900247          A      19990504    US 1996-777306          19961227
PRIORITY APPLN. INFO.:                       FR 1995-15701       A   19951229
AB   Bioadhesive pharmaceutical composition for the controlled release of active
     agents in buccal cavity or through nasal, vaginal, and rectal
     mucosa are claimed.  The bioadhesive compns. contain vinyl
     acetate-vinylpyrrolidone copolymer (I) and polysaccharides.
     Dihydroergotamine monomethanesulfonate 0.15, I 5, and ethanol:0.1N HCl
     (50:50) 10 mL were mixed to obtain a homogeneous solution followed by addition
     of 0.5 g propylene glycol.  The mixture thus obtained was spread on an
     ethylene-vinyl acetate film and dried at room temperature for 2h.  Disks of 1
cm
     diameter having thickness of 0.2 mm were cut from above film for use.
IT   52293-23-9, Piribedil monomethane sulfonate
     RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
```

(controlled-release bioadhesive pharmaceutical compns. containing vinyl acetate-vinylpyrrolidone copolymer)

RN 52293-23-9 CAPLUS

CN Pyrimidine, 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 3605-01-4

CMF C16 H18 N4 O2



CM 2

CRN 75-75-2

CMF C H4 O3 S

=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	85.70	271.80
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.02	-9.02

STN INTERNATIONAL LOGOFF AT 13:06:29 ON 06 APR 2009